Blog | HemaCare

An independent study published by the MD Anderson Cancer Center in Houston TX cites using HemaCare PBMCs to take a closer look at the SARS-CoV-2 virus to identify which of its peptide sequences would make the most effective vaccine targets.

Early in the COVID-19 pandemic, the primary goal for scientists across the globe was to save lives by developing a safe, working vaccine as quickly as possible. To that end, they succeeded admirably; with several vaccines approved, doctors finally have a powerful way to fight back against this deadly disease.

Pharmaceutical giant Pfizer cite the use of HemaCare starting materials in the development of a new immune cell validation assay. ^[1]

The new assay is designed to measure dendritic cell activation as a predictor of immunogenicity, so that scientists can assess risk early in the development of new pharmaceuticals. Low immunogenicity points toward a better overall safety profile.

Dendritic cells (DC) are antigen-presenting cells, involved in the initiation and regulation of the immune response. Since DC are tumor-infiltrating cells central to the initiation of antigen-specific immunity, they have long been investigated as a means of improving cancer immunotherapy.

Anaphylaxis is a severe allergic response characterized by the development of hives, swelling, and dramatic drops in blood pressure. It is estimated that 1,500 people in the United States die yearly from anaphylaxis. A plethora of substances can elicit allergic reactions, and the exact allergen is often unknown. What is known is that an allergen binds to IgE found on mast cells, and this leads to the release of inflammatory mediators such as histamine, the substances responsible for the allergic response. Mast cells are found in tissue, yet can respond to allergens in the blood via a mechanism that is not well understood.

Research efforts across different disciplines are beginning to uncover biological factors that underlie racial differences in health status and disease severity. One common condition with a prevalence of 7.3 percent among U.S. adults is atopic dermatitis. In terms of prevalence and disease severity, African Americans are disproportionately affected when compared to European Americans.

Dendritic cell molecules within the body’s immune system can be modified to improve our ability to combat viral and bacterial infections. 

The body’s immune system is designed to protect it from invading organisms and other pathogens. However, the immune system alone may not always be able to combat viral and bacterial infections, and antimicrobial therapies are implemented. A different approach would be to manipulate or affect immune system cells to control infections. Researchers at the Scripps Research Institute, La Jolla, CA have discovered that immune system molecules exist that can make people more vulnerable to bacterial infections, and that modifying expression or function of these immune molecules can enhance resistance to detrimental bacterial infections.